Case Report: Significant Response to the Combination of Lenvatinib and Immune Checkpoint Inhibitor in a Patient With Heavily Pretreated Metastatic Triple Negative Breast Cancer

BACKGROUND: Triple negative breast cancer (TNBC) has poor prognosis without targetable mutations. The combination of lenvatinib and pembrolizumab has shown clinical activity in different types of solid tumors. CASE PRESENTATION: We report a case of one patient with metastatic TNBC who has been heavi...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Jin Sun, Yost, Susan E., Yuan, Yuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7830150/
https://www.ncbi.nlm.nih.gov/pubmed/33505906
http://dx.doi.org/10.3389/fonc.2020.582185

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7830150/
https://www.ncbi.nlm.nih.gov/pubmed/33505906
http://dx.doi.org/10.3389/fonc.2020.582185

Ejemplares similares